The Clinical Trial, the commencement of which was one of the Company's targets for 2016, began on time as planned. At this stage, its date of completion cannot be estimated (which mainly depends on the enrollment rate of the additional subjects). The Company will continue to update of any material development and information it will receive on the course of the Clinical Trial and its results.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Because such statements deal with future events and are based on Therapix's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Therapix could differ materially from those described in or implied by the statements in this press release. For example, forward-looking statements include statements regarding the Company's plans with respect to its clinical trials and its intent to report material developments and information regarding such trials. In addition, historic results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in Therapix Biosciences Ltd.'s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) and in subsequent filings with the SEC. Except as otherwise required by law, Therapix disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
1. The drug is a combination between the THC and PEA compounds.
2. (Investigator initiated) Investigational New Drug - an application for a drug examination proceeding by the FDA, for the purpose of performing clinical trials in humans, that was filed and is being handled by investigators at the University, with the Company's financing.
3. The two primary investigators of the Clinical Trial also hold office as members of the Company's SAB.
For further details, Goldfinger Communications, Irit Yosilevitch, +972-052-3887799
SOURCE Therapix Biosciences